Antipsychotics increase mortality in elderly patients with dementia. (n.d.). http://www.npc.nhs.uk/merec/cns/dementia/merec_extra_no39.php
Aricept Tablets - Summary of Product Characteristics (SPC) - (eMC). (n.d.). http://www.medicines.org.uk/emc/medicine/577/SPC/Aricept
Bhasin, M., Rowan, E., Edwards, K., & McKeith, I. (2007). Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis. International Journal of Geriatric Psychiatry, 22(9), 890–895. https://doi.org/10.1002/gps.1759
British National Formulary. (n.d.). http://www.bnf.org/bnf/index.htm
Centre for Medicines Optimisation - MTRAC | Independent Medicines Review | Midlands Therapeutics Review & Advisory Committee | Centre for Medicines Optimisation | Keele University. (n.d.). http://centreformedicinesoptimisation.co.uk/mtrac/
Chronic obstructive pulmonary disease. (n.d.). http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease
Clinical guidelines, CG42 - Issued: November 2006. (n.d.). http://guidance.nice.org.uk/CG42
Coeliac disease: recognition, assessment and management | Guidance and guidelines | NICE. (n.d.). https://www.nice.org.uk/guidance/ng20
Commissioners and healthcare professionals - Training videos. (n.d.). http://healthcheck.nhs.uk/commissioners_and_providers/training/training_videos1/
Complete Guide to Behavioural and Psychological symptoms of Dementia. (n.d.). http://www.ipa-online.org/
CPPE - Centre for Pharmacy Postgraduate Education. (n.d.). https://www.cppe.ac.uk/
DH Living well with dementia: a National Dementia Strategy. (n.d.). https://www.gov.uk/government/organisations/department-of-health
Ebixa 5mg/pump actuation oral solution, 20mg and 10 mg Tablets and Treatment Initiation Pack - Summary of Product Characteristics (SPC) - (eMC). (n.d.). http://www.medicines.org.uk/EMC/medicine/10175/SPC/rEbxia+5mg+pump+oral+solution%252c+20mg+and+10+mg+tablets+and+Treatment+Initiation+Pack/
Electronic Medicines Compendium (eMC). (n.d.-a). http://www.medicines.org.uk/emc/
Electronic Medicines Compendium (eMC). (n.d.-b). http://www.medicines.org.uk/emc/
Electronic Medicines Compendium (eMC). (n.d.-c). https://www.medicines.org.uk/emc/
Evidence Search - Search Engine for Evidence in Health and Social Care. (n.d.-a). https://www.evidence.nhs.uk/
Evidence Search - Search Engine for Evidence in Health and Social Care. (n.d.-b). https://www.evidence.nhs.uk/
Evidence Search - Search Engine for Evidence in Health and Social Care. (n.d.-c). https://www.evidence.nhs.uk/
Exelon - Summary of Product Characteristics (SPC) - (eMC). (n.d.). https://www.medicines.org.uk/emc/search?q=Exelon+
GOV.UK. (n.d.). https://www.gov.uk/government/organisations/department-of-health
Greene, R. J., & Harris, N. D. (2008). Pathology and therapeutics for pharmacists: a basis for clinical pharmacy practice (3rd ed). Pharmaceutical Press.
Heart failure - chronic. (n.d.). http://cks.nice.org.uk/heart-failure-chronic
Hubley, J., Copeman, J., & Woodall, J. (2013). Practical health promotion (2nd ed). Polity Press.
Kavirajan, H., & Schneider, L. S. (2007). Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. The Lancet Neurology, 6(9), 782–792. https://doi.org/10.1016/S1474-4422(07)70195-3
Kumar, P. J., & Clark, M. L. (2012). Kumar & Clark’s clinical medicine (8th ed). Saunders Elsevier. https://www.dawsonera.com/abstract/9780702053047
Laverack, G. (2007). Health promotion practice: building empowered communities. Open University Press. https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=nlebk&AN=234222&site=ehost-live&scope=site&custid=s8454451
Macdowall, W., Bonell, C., & Davies, M. (2006). Health promotion practice: Vol. Understanding public health. Open University Press.
Maher, A. R. (2011). Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in AdultsA Systematic Review and Meta-analysis. JAMA: The Journal of the American Medical Association, 306(12). https://doi.org/10.1001/jama.2011.1360
Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011). Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults. JAMA, 306(12). https://doi.org/10.1001/jama.2011.1360
Map of Medicine | Home. (n.d.). http://www.mapofmedicine.com/
Martinón-Torres, G., Fioravanti, M., & Grimley Evans, J. (2004). Trazodone for agitation in dementia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD004990
Medicines Information - Evidence Search - Search Engine for Evidence in Health and Social Care. (n.d.). https://www.evidence.nhs.uk/
Medicines Use Review and Prescription Intervention service. (n.d.). http://psnc.org.uk/wp-content/uploads/2013/06/MUR-service-spec-Aug-2013-changes_FINAL.pdf
Miller, W. R., & Rollnick, S. (2013). Motivational interviewing: helping people change: Vol. Applications of motivational interviewing (3rd ed). Guilford Press.
National Institute for Health and Care Excellence. (n.d.). http://www.nice.org.uk/
NHS Health Check - NHS Choices. (n.d.). http://www.nhs.uk/Conditions/nhs-health-check/Pages/NHS-Health-Check.aspx
NICE Clinical Knowledge Summaries (CKS). (n.d.). http://cks.nice.org.uk/
NPC | National Prescribing Centre. (n.d.-a). https://www.guidelinesinpractice.co.uk
NPC | National Prescribing Centre. (n.d.-b). https://www.guidelinesinpractice.co.uk
Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide. (n.d.). https://www.alzheimers.org.uk/bpsdguide
Pierre N. Tariot, M.D.; Rosemary Erb, R.N., B.S.N.; Carol Ann Podgorski, Ph.D.; Christopher Cox, Ph.D.; Shirish Patel, M.D.; Laura Jakimovich, M.S., R.N.; Carrie Irvine, B.A. (1998). Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia. PsychiatryOnline | American Journal of Psychiatry | Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia, 155(1), 54–61. https://doi.org/10.1176/ajp.155.1.54
Prochaska, J. O., Norcross, J. C., & DiClemente, C. C. (1994). Changing for good. William Morrow.
Reminyl Tablets - Summary of Product Characteristics (SPC) - (eMC). (n.d.).
Risperdal Tablets, Liquid & Quicklet - Summary of Product Characteristics (SPC) - (eMC). (n.d.). http://www.medicines.org.uk/emc/document.aspx?documentid=12818&docType=SPC
Rollnick, S., Mason, P., & Butler, C. (1999). Health behavior change: a guide for practitioners. Churchill Livingstone.
Rollnick, S., Miller, W. R., & Butler, C. (2008). Motivational interviewing in health care: helping patients change behavior: Vol. Applications of motivational interviewing. Guilford Press.
Royal Pharmaceutical Society (RPS). (n.d.). http://www.rpharms.com/home/home.asp
Scottish Intercollegiate Guidelines Network (SIGN). (n.d.). http://www.sign.ac.uk/
Service specification - New Medicine Service (NMS). (n.d.). http://psnc.org.uk/wp-content/uploads/2013/06/NMS-service-spec-Aug-2013-changes_FINAL.pdf
Sube Banerjee. (12 C.E.). The use of antipsychotic medication for people with dementia: Time for action. A report for the Minister of State for Care Services. http://psychrights.org/research/digest/nlps/BanerjeeReportOnGeriatricNeurolepticUse.pdf
TA217 Alzheimer’s disease - donepezil, galantamine, rivastigmine and memantine: guidance (MS Word format). (n.d.). http://guidance.nice.org.uk/TA217/Guidance/doc/English
Treatment protocol by NHS Medway: Treatment of Behaviour That Challenges. (n.d.). http://www.kmpt.nhs.uk/policies
Waldemar, G., Hyvärinen, M., Josiassen, M. K., Kørner, A., Lehto, H., & Wetterberg, P. (2008). Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer’s disease. International Journal of Geriatric Psychiatry, 23(9), 979–981. https://doi.org/10.1002/gps.1979
Walker, R., & Whittlesea, C. (2012). Clinical pharmacy and therapeutics (5th ed). Churchill Livingstone. https://www.vlebooks.com/Product/Index/173020?page=0&startBookmarkId=-1
Warner, J., & Smith, T. (n.d.). The rise and fall of antipsychotic prescribing in dementia. Where do we go from here? The Rise and Fall of Antipsychotic Prescribing in Dementia, 14(2), 24–27.
